TROUBLE VIEWING? Click Here to view the Promo card on the web
SIGN-UP NOW! SIGN-UP NOW! Click to become a Member for Free!
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

December 05th 2017:Encore: The Latest Developments in C. diff Research and Treatment.

Join us with our guest, Dr Mary Beth Dorr, PhD, Clinical Director, Clinical Research, Infectious Diseases, Merck & Co., Inc. as Mary Beth provides us with an overview of a C. diff. infection, the challenges of recurrence, latest clinical research overview, current treatment landscape, and pending new C. diff infection treatment guidelines from the Infectious Diseases Society of America (IDSA) that are anticipated to come out this fall.

Share Email SHARE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guest

Guest Image

Dr Mary Beth Dorr,PhD, Clinical Director Merck & Co., Inc.

Dr. Mary Beth Dorr is the product development lead for ZINPLAVA (bezlotoxumab), a human monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects.She has an undergraduate pharmacy degree from the University of the Sciences’ Philadelphia College of Pharmacy and completed a clinical pharmacy residency at the Veteran's Administration Hospital in Philadelphia,completed her PhD in pharmaceutics with an emphasis on pharmacokinetics and drug metabolism at the University of North Carolina in Chapel Hill. She joined the pharmaceutical industry in 1988, and has devoted her career to the design and implementation of Phase 1 to 4 clinical trials, primarily for anti-in
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
Facebook Twitter Linkedin Social Media